Wilson Therapeutics AB (Publ) Interim report January 1 - March 31, 2018
JANUARY 1 – MARCH 31, 2018 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 68.9 M (loss: 31.4) · Loss per share, before and after dilution, totaled SEK 2.43 (loss: 1.22) · At March 31, cash and cash equivalents amounted to SEK 426.7 M (339.3) SIGNIFICANT EVENTS DURING THE PERIOD · First patient enrolled in pivotal Phase 3 FOCuS trial · New patents filed SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD · Public cash offer to acquire Wilson Therapeutics announced · Preliminary long-term data from the extension phase of the